Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Postmenopausal hormone replacement therapy and atherosclerosis.

Jennifer E Ho1, Lori Mosca

  • 1Columbia-Weill Cornell Preventive Cardiology Program, New York Presbyterian Hospital, 622 West 168th Street, PH 10-203B, New York, NY 10032, USA.

Current Atherosclerosis Reports
|August 7, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association of eicosanoids with lung structure and function: Findings from the Multi-Ethnic Study of Atherosclerosis lung study and Framingham Heart Study.

PloS one·2026
Same author

What Are HFpEF Mimics and What Are They Mimicking? Insights Into Our Conceptualization of Heart Failure With Preserved Ejection Fraction as a Disease.

Journal of cardiac failure·2026
Same author

Treatment of Cardiometabolic Risk Factors Among U.S. Adults With Cardiovascular-Kidney-Metabolic Syndrome.

Journal of the American College of Cardiology·2026
Same author

Menopausal Age, Number of Live Births, and Risk of Atrial Fibrillation: The Cardiovascular Health Study.

Journal of the American Heart Association·2026
Same author

Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.

Journal of the American College of Cardiology·2026
Same author

Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.

Circulation·2026

Hormone replacement therapy (HRT) effects on cardiovascular disease (CVD) are complex. Current evidence does not support HRT for secondary CVD prevention, and combination therapy shows early risks without overall benefit.

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Pharmacology

Background:

  • The role of postmenopausal hormone replacement therapy (HRT) in cardiovascular disease (CVD) prevention is complex and has evolved.
  • Estrogen's vasoprotective potential is mediated by genomic and rapid non-genomic effects on vascular cells.
  • These effects influence vasodilation, coagulation, inflammation, and vascular injury response, with potential for both benefit and harm.

Purpose of the Study:

  • To review the evolving role of HRT in cardiovascular disease (CVD) prevention.
  • To elucidate the multiple mechanisms underlying HRT's cardiovascular effects.
  • To discuss current guidelines and future directions for HRT in CVD prevention.

Main Methods:

  • Literature review of studies on HRT and cardiovascular outcomes.

Related Experiment Videos

  • Analysis of molecular signaling pathways and biologic mechanisms of estrogen action in vascular cells.
  • Evaluation of current clinical guidelines and primary/secondary prevention trial results.

    • Main Results:

    • Current guidelines do not recommend HRT for secondary CVD prevention.
    • Primary prevention trials with combination estrogen-progestin show increased early cardiovascular risk and no overall health benefit.
    • The role of estrogen alone in primary CVD prevention requires further investigation from ongoing trials.

    Conclusions:

    • HRT's cardiovascular effects are multifaceted, involving various molecular pathways.
    • Combination HRT is not recommended for primary or secondary CVD prevention due to risks.
    • Future HRT strategies for CVD prevention may involve targeting pre-atherosclerotic stages and identifying genetically susceptible individuals.